Hormonal
IGF-1 deficiency is a key pathophysiological factor in metabolic syndrome, and restoring physiological levels of IGF-1 via replacement therapy can improve insulin sensitivity, glucose homeostasis, and lipid metabolism.
If you have metabolic syndrome or type 2 diabetes and standard lifestyle changes aren't working, your body might be deficient in IGF-1, a hormone that helps regulate blood sugar and fats. Restoring IGF-1 to normal, natural levels (not high doses) may help improve your body's sensitivity to insulin and metabolic health. This should only be done under medical supervision to ensure levels stay within a safe, physiological range.
Based on the available data we propose IGF-1 as a key hormone in the pathophysiology of metabolic syndrome; due to its implications in the metabolism of carbohydrates and lipids. Previous data demonstrates how IGF-1 can be an effective option in the treatment of this worldwide increasing condition. It has to distinguished that the replacement therapy should be only undertaken to restore the physiological levels, never to exceed physiological ranges.
Why this rating
The paper is a review of multiple studies (in vitro and in vivo) from 1963-2015, citing numerous animal models and some human data, but lacks a single large-scale randomized controlled trial conclusion.
Source
Insulin-like growth factor-1 deficiency and metabolic syndrome
Gabriel A. Aguirre et al. · Journal of Translational Medicine · 2016
DOI 10.1186/s12967-015-0762-z
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →